[1]
|
Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71: 209-249. doi: 10.3322/caac.21660 |
[2]
|
Liang H, Fan JH, Qiao YL. Epidemiology, etiology, and prevention of esophageal squamous cell carcinoma in China[J]. Cancer Biol Med, 2017, 14: 33-41. doi: 10.20892/j.issn.2095-3941.2016.0093 |
[3]
|
Allemani C, Matsuda T, Di Carlo V, et al. Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries[J]. Lancet, 2018, 391: 1023-1075. doi: 10.1016/S0140-6736(17)33326-3 |
[4]
|
Siegel RL, Miller KD, Fuchs HE, et al. Cancer statistics, 2022[J]. CA Cancer J Clin, 2022, 72: 7-33. doi: 10.3322/caac.21708 |
[5]
|
Van Putten M, De Vos-Geelen J, Nieuwenhuijzen GaP, et al. Long-term survival improvement in oesophageal cancer in the Netherlands[J]. Eur J Cancer, 2018, 94: 138-147. doi: 10.1016/j.ejca.2018.02.025 |
[6]
|
Zeng H, Chen W, Zheng R, et al. Changing cancer survival in China during 2003-15: a pooled analysis of 17 population-based cancer registries[J] Lancet Glob Health, 2018, 6: e555-e567. doi: 10.1016/S2214-109X(18)30127-X |
[7]
|
Rice TW, Rusch VW, Apperson-Hansen C, et al. World-wide esophageal cancer collaboration[J]. Dis Esophagus, 2009, 22: 1-8. doi: 10.1111/j.1442-2050.2008.00901.x |
[8]
|
Watanabe M, Tachimori Y, Oyama T, et al. Comprehensive registry of esophageal cancer in Japan, 2013[J]. Esophagus, 2021, 18: 1-24. doi: 10.1007/s10388-020-00785-y |
[9]
|
毛友生, 高树庚, 王群, 等. 中国食管癌临床流行特征及外科治疗概况大数据分析[J]. 中华肿瘤杂志, 2020, 42: 228-233. Mao YS, Gao SG, Wang Q, et al. Epidemiological characteristic and current status of surgical treatment for esophageal cancer by analysis of national registry database[J]. Zhonghua Zhongliu Zazhi, 2020, 42: 228-233. doi: 10.3760/cma.j.cn112152-20191112-00729
Mao YS, Gao SG, Wang Q, et al. Epidemiological characteristic and current status of surgical treatment for esophageal cancer by analysis of national registry database[J]. Zhonghua Zhongliu Zazhi, 2020, 42: 228-233. doi: 10.3760/cma.j.cn112152-20191112-00729 |
[10]
|
Yang HX, Ling L, Zhang X, et al. Outcome of elderly patients with oesophageal squamous cell carcinoma after surgery[J]. Br J Surg, 2010, 97: 862-867. doi: 10.1002/bjs.7005 |
[11]
|
Bohanes P, Yang D, Chhibar RS, et al. Influence of sex on the survival of patients with esophageal cancer[J]. J Clin Oncol, 2012, 30: 2265-2272. doi: 10.1200/JCO.2011.38.8751 |
[12]
|
He Y, Liang D, Du L, et al. Clinical characteristics and survival of 5283 esophageal cancer patients: A multicenter study from eighteen hospitals across six regions in China[J]. Cancer Commun (Lond), 2020, 40: 531-544. doi: 10.1002/cac2.12087 |
[13]
|
Wang BY, Goan YG, Hsu PK, et al. Tumor length as a prognostic factor in esophageal squamous cell carcinoma[J]. Ann Thorac Surg, 2011, 91: 887-893. doi: 10.1016/j.athoracsur.2010.11.011 |
[14]
|
Smyth EC, Lagergren J, Fitzgerald RC, et al. Oesophageal cancer[J]. Nat Rev Dis Primers, 2017, 3: 17048. doi: 10.1038/nrdp.2017.48 |
[15]
|
Miyata H, Yamasaki M, Kurokawa Y, et al. Prognostic value of an inflammation-based score in patients undergoing pre-operative chemotherapy followed by surgery for esophageal cancer[J]. Exp Ther Med, 2011, 2: 879-885. doi: 10.3892/etm.2011.308 |
[16]
|
Su D, Zhou X, Chen Q, et al. Prognostic Nomogram for Thoracic Esophageal Squamous Cell Carcinoma after Radical Esophagectomy[J]. PLoS One, 2015, 10: e0124437. doi: 10.1371/journal.pone.0124437 |
[17]
|
Shao Y, Ning Z, Chen J, et al. Prognostic nomogram integrated systemic inflammation score for patients with esophageal squamous cell carcinoma undergoing radical esophagectomy[J]. Sci Rep, 2015, 5: 18811. doi: 10.1038/srep18811 |
[18]
|
Chen GP, Huang Y, Yang X, et al. A Nomogram to Predict Prognostic Value of Red Cell Distribution Width in Patients with Esophageal Cancer[J]. Mediators Inflamm, 2015, 2015: 854670. |
[19]
|
Liu JS, Huang Y, Yang X, et al. A nomogram to predict prognostic values of various inflammatory biomarkers in patients with esophageal squamous cell carcinoma[J]. Am J Cancer Res, 2015, 5: 2180-2189. |
[20]
|
Yu S, Zhang W, Ni W, et al. Nomogram and recursive partitioning analysis to predict overall survival in patients with stage ⅡB-Ⅲ thoracic esophageal squamous cell carcinoma after esophagectomy[J]. Oncotarget, 2016, 7: 55211-55221. doi: 10.18632/oncotarget.10904 |
[21]
|
Duan J, Deng T, Ying G, et al. Prognostic nomogram for previously untreated patients with esophageal squamous cell carcinoma after esophagectomy followed by adjuvant chemotherapy[J]. Jpn J Clin Oncol, 2016, 46: 336-343. doi: 10.1093/jjco/hyv206 |
[22]
|
Chen S, Yang X, Feng JF. A novel inflammation-based prognostic score for patients with esophageal squamous cell carcinoma: the c-reactive protein/prognostic nutritional index ratio[J]. Oncotarget, 2016, 7: 62123-62132. doi: 10.18632/oncotarget.11389 |
[23]
|
Deng W, Wang Q, Xiao Z, et al. A prognostic nomogram for overall survival after neoadjuvant radiotherapy or chemoradiotherapy in thoracic esophageal squamous cell carcino-ma: a retrospective analysis[J]. Oncotarget, 2017, 8: 41102-41112. doi: 10.18632/oncotarget.17062 |
[24]
|
Deng W, Zhang W, Yang J, et al. Nomogram to Predict Overall Survival for Thoracic Esophageal Squamous Cell Carcinoma Patients After Radical Esophagectomy[J]. Ann Surg Oncol, 2019, 26: 2890-2898. doi: 10.1245/s10434-019-07393-w |
[25]
|
Li X, Xu J, Zhu L, et al. A novel nomogram with preferable capability in predicting the overall survival of patients after radical esophageal cancer resection based on accessible clinical indicators: A comparison with AJCC staging[J]. Cancer Med, 2021, 10: 4228-4239. doi: 10.1002/cam4.3878 |
[26]
|
Shao CY, Liu XL, Yao S, et al. Development and validation of a new clinical staging system to predict survival for esophageal squamous cell carcinoma patients: Application of the nomogram[J]. Eur J Surg Oncol, 2021, 47: 1473-1480. doi: 10.1016/j.ejso.2020.12.004 |
[27]
|
Jung HA, Adenis A, Lee J, et al. Nomogram to predict treatment outcome of fluoropyrimidine/platinum-based chemotherapy in metastatic esophageal squamous cell carcinoma[J]. Cancer Res Treat, 2013, 45: 285-294. doi: 10.4143/crt.2013.45.4.285 |
[28]
|
Wang J, Wu LL, Zhang Y, et al. Establishing a survival prediction model for esophageal squamous cell carcinoma based on CT and histopathological images[J]. Phys Med Biol, 2021, 66. doi: 10.1088/1361-6560/ac1020. |
[29]
|
Zhao P, Yan W, Fu H, et al. Efficacy of postoperative adjuvant chemotherapy for esophageal squamous cell carcinoma: A meta-analysis[J]. Thorac Cancer, 2018, 9: 1048-1055. doi: 10.1111/1759-7714.12787 |
[30]
|
Lin HN, Chen LQ, Shang QX, et al. A meta-analysis on surgery with or without postoperative radiotherapy to treat squamous cell esophageal carcinoma[J]. Int J Surg, 2020, 80: 184-191. doi: 10.1016/j.ijsu.2020.06.046 |
[31]
|
Kang J, Chang JY, Sun X, et al. Role of Postoperative Concurrent Chemoradiotherapy for Esophageal Carcinoma: A meta-analysis of 2165 Patients[J]. J Cancer, 2018, 9: 584-593. doi: 10.7150/jca.20940 |
[32]
|
National Comprehensive Cancer Network. Esophageal and Esophagogastric Junction Cancers[EB/OL]. (2021-08-03)[2022-01-14]. https://www.nccn.org/professionals/physician_gls/pdf/esophageal.pdf. |
[33]
|
Noh SH, Park SR, Yang HK, et al. Adjuvant capecitab-ine plus oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): 5-year follow-up of an open-label, randomised phase 3 trial[J]. Lancet Oncol, 2014, 15: 1389-1396. doi: 10.1016/S1470-2045(14)70473-5 |
[34]
|
Smalley SR, Benedetti JK, Haller DG, et al. Updated analysis of SWOG-directed intergroup study 0116: a phase Ⅲ trial of adjuvant radiochemotherapy versus observation after curative gastric cancer resection[J]. J Clin Oncol, 2012, 30: 2327-2333. doi: 10.1200/JCO.2011.36.7136 |
[35]
|
Rice TW, Blackstone EH, Rusch VW. 7th edition of the AJCC Cancer Staging Manual: esophagus and esophagogastric junction[J]. Ann Surg Oncol, 2010, 17: 1721-1724. doi: 10.1245/s10434-010-1024-1 |
[36]
|
Harrell Jr FE, Harrell Jr MFE. Package'hmisc '[J]. CRAN2018, 2019, 2019: 235-236. |
[37]
|
Wang Y, Li J, Xia Y, et al. Prognostic nomogram for intrahepatic cholangiocarcinoma after partial hepatectomy[J]. J Clin Oncol, 2013, 31: 1188-1195. doi: 10.1200/JCO.2012.41.5984 |
[38]
|
Tian H, Yang W, Hu Y, et al. Estimating cancer incidence based on claims data from medical insurance systems in two areas lacking cancer registries in China[J]. EClinicalMedicine, 2020, 20: 100312. doi: 10.1016/j.eclinm.2020.100312 |
[39]
|
He Z, Ke Y. Precision screening for esophageal squamous cell carcinoma in China[J]. Chin J Cancer Res, 2020, 32: 673-682. doi: 10.21147/j.issn.1000-9604.2020.06.01 |
[40]
|
Jiang YQ, Chen SF, Zhu B. Prognostic factors and family history for survival of esophageal squamous cell carcinoma patients after surgery[J]. Ann Thorac Surg, 2010, 90: 908-913. doi: 10.1016/j.athoracsur.2010.05.060 |
[41]
|
Visser E, Markar SR, Ruurda JP, et al. Prognostic Value of Lymph Node Yield on Overall Survival in Esophageal Cancer Patients: A Systematic Review and Meta-analysis[J]. Ann Surg, 2019, 269: 261-268. doi: 10.1097/SLA.0000000000002824 |
[42]
|
Anandavadivelan P, Lagergren P. Cachexia in patients with oesophageal cancer[J]. Nat Rev Clin Oncol, 2016, 13: 185-198. doi: 10.1038/nrclinonc.2015.200 |
[43]
|
Huang XZ, Yang YC, Chen Y, et al. Preoperative Anemia or Low Hemoglobin Predicts Poor Prognosis in Gastric Cancer Patients: A Meta-Analysis[J]. Dis Markers, 2019, 2019: 7606128. |
[44]
|
Lu Z, Fang Y, Liu C, et al. Early Interdisciplinary Supportive Care in Patients With Previously Untreated Metastatic Esophagogastric Cancer: A Phase Ⅲ Randomized Controlled Trial[J]. J Clin Oncol, 2021, 39: 748-756. doi: 10.1200/JCO.20.01254 |
[45]
|
Zhang SS, Yang H, Xie X, et al. Adjuvant chemotherapy versus surgery alone for esophageal squamous cell carcinoma: a meta-analysis of randomized controlled trials and nonrandomized studies[J]. Dis Esophagus, 2014, 27: 574-584. doi: 10.1111/dote.12073 |
[46]
|
Ni W, Yu S, Zhang W, et al. A phase-Ⅱ/Ⅲ randomized controlled trial of adjuvant radiotherapy or concurrent chemoradiotherapy after surgery versus surgery alone in patients with stage-ⅡB/Ⅲ esophageal squamous cell carcinoma[J]. BMC Cancer, 2020, 20: 130. doi: 10.1186/s12885-020-6592-2 |
[47]
|
Rucker AJ, Raman V, Jawitz OK, et al. The Impact of Adjuvant Therapy on Survival After Esophagectomy for Node-negative Esophageal Adenocarcinoma[J]. Ann Surg, 2022, 275: 348-355. doi: 10.1097/SLA.0000000000003886 |